![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
TAK-660-403 4+
ERT,INC
-
- Free
Screenshots
Description
An app for the TAK-660-403 Protocol. Evaluation of long-term safety of ADYNOVI / ADYNOVATE(Antihaemophilic Factor [Recombinant] PEGylated, rurioctocog alfa pegol) in patients with haemophilia A – An ADYNOVI / ADYNOVATE Post-Authorisation Safety Study (PASS)
What’s New
Version 1.2
- Bug fixes for iOS 17
App Privacy
The developer, ERT,INC, indicated that the app’s privacy practices may include handling of data as described below. For more information, see the developer’s privacy policy.
Data Not Collected
The developer does not collect any data from this app.
Privacy practices may vary based on, for example, the features you use or your age. Learn More
Information
- Provider
- ERT, INC
- Size
- 40 MB
- Category
- Medical
- Compatibility
-
- iPhone
- Requires iOS 10.0 or later.
- iPad
- Requires iPadOS 10.0 or later.
- iPod touch
- Requires iOS 10.0 or later.
- Apple Vision
- Requires visionOS 1.0 or later.
- Languages
-
English
- Age Rating
- 4+
- Copyright
- © ERT
- Price
- Free